Skip to main content
European Commission logo print header

An innovative family of antibiotics to fight multi-resistant bacteria

Project description

Engineering a novel class of peptides to develop new antibiotics

Antimicrobial resistance is a global issue that affects all countries. A successful response also needs to address diagnostics, vaccines, and alternatives to antibiotics for human and animal health. The ERC-funded ENTRAP project will study the current antibiotic resistance crisis that is notably connected to the massive misuse of antibiotics and the lack of novel and efficient compounds. Specifically, it will target ribosomally synthesised and post-translationally modified peptides (RiPP). The project’s overall aim is to engineer a novel class of RiPPs in order to develop innovative antibiotics. As such, it will seek solutions to challenges related to the synthesis, stability and bioavailability of antibiotics.

Objective

Antibiotic resistant bacteria are rapidly emerging worldwide. This antibiotic resistance crisis is notably connected to the massive misuse of antibiotics and the lack of novel and efficient compounds. With countless structures and properties, natural products including ribosomally synthesized and post-translationally modified peptides (RiPP) are a promising source of antibiotics . However, their development as effective antibiotics faces many challenges related notably to their synthesis, stability and bioavailability. In the frame of this project, we aim to engineer a novel class of RiPPs in order to develop innovative antibiotics.

Host institution

INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Net EU contribution
€ 150 000,00
Address
147 RUE DE L'UNIVERSITE
75007 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)